中国健康受试者单次和多次口服Obicetrapib片的药代动力学、药效学和安全性的随机、平行分组、开放、单中心I期临床试验。
[Translation] A randomized, parallel-group, open-label, single-center phase I clinical trial to investigate the pharmacokinetics, pharmacodynamics, and safety of single and multiple oral administration of Obicetrapib tablets in healthy Chinese subjects.
主要目的:
评价中国健康受试者单次和多次口服Obicetrapib后的PK特征。
次要目的:
评价中国健康受试者单次和多次口服Obicetrapib后的PD特征,探索药物的剂量-暴露-效应关系;
评价中国健康受试者单次和多次口服Obicetrapib后的安全性。
[Translation] Primary purpose:
To evaluate the PK characteristics of Obicetrapib after single and multiple oral administration in healthy Chinese subjects.
Secondary purpose:
To evaluate the PD characteristics of Obicetrapib after single and multiple oral administration in healthy Chinese subjects, and to explore the dose-exposure-effect relationship of the drug;
To evaluate the safety of Obicetrapib after single and multiple oral administration in healthy Chinese subjects.
100 Clinical Results associated with Nanjing Sirui Biotechnology Co., Ltd.
0 Patents (Medical) associated with Nanjing Sirui Biotechnology Co., Ltd.
100 Deals associated with Nanjing Sirui Biotechnology Co., Ltd.
100 Translational Medicine associated with Nanjing Sirui Biotechnology Co., Ltd.